Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 8/20 | 0.41 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3554553 | 0.91 | IGF1R (0.45) | IGF1RPLK1FLT3CDK2SLC2A1 | |
| SCHEMBL3556604 | 0.88 | IGF1R (0.43) | IGF1RPLK1FLT3CDK2SLC2A1 | |
| SCHEMBL3551627 | 0.83 | PLK1 (0.46) | IGF1RPLK1 | |
| SCHEMBL2199282 | 0.83 | IGF1R (0.39) | IGF1RPLK1CDK2 | |
| SCHEMBL3559021 | 0.83 | IGF1R (0.39) | IGF1RPLK1FLT3CDK2 | |
| SCHEMBL3547042 | 0.83 | IGF1R (0.39) | IGF1RPAK1PLK1FLT3CDK2 | |
| SCHEMBL3550094 | 0.83 | PLK1 (0.39) | IGF1RPLK1CDK2 | |
| SCHEMBL3549490 | 0.82 | PLK1 (0.40) | IGF1RPLK1CDK2 | |
| SCHEMBL3543396 | 0.82 | IGF1R (0.43) | IGF1RPLK1CDK2 | |
| SCHEMBL3555797 | 0.81 | CDK2 (0.44) | IGF1RPLK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | IGF1R 101/4885PAK1 384/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.